Health

Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026

March 08, 2026 14:00 ET  | Source: Xenon Pharmaceuticals Inc. VANCOUVER, British Columbia and BOSTON, March 08, 2026 (GLOBE NEWSWIRE)…

4 months ago

Crescent Biopharma Announces Grants of Inducement Awards

March 06, 2026 16:15 ET  | Source: Crescent Biopharma, Inc. WALTHAM, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma,…

4 months ago

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and…

4 months ago

Curaechoice and Health Benefit Alliance Partner to Deliver No-Cost Healthcare to 161,000 Members Across 42 States

Strategic collaboration expands access to $0 medical, pharmacy, dental, and vision benefits for more than 1,000 self-insured employers nationwide March…

4 months ago

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 06, 2026 17:33 ET  | Source: Tango Therapeutics Sub, Inc BOSTON, March 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics,…

4 months ago

Karylief Tinnitus Supplement Claims Evaluated: 2026 Consumer Report Examines Karylief Hearing Support Ingredients, Proprietary Blend Transparency, and Research Context

Aurora, CO, March 06, 2026 (GLOBE NEWSWIRE) -- This article is for informational purposes only. It is not medical advice.…

4 months ago

MagnesiumFreeze Sciatic Nerve Claims Evaluated: Consumer Research Report Examines Magnesium Niacinamide Relief Topical Cream Ingredients, NAD+ Science, and Sciatic Nerve Support Discussions

Spearfish, SD, March 06, 2026 (GLOBE NEWSWIRE) -- This article is an informational consumer research report and does not constitute…

4 months ago

AIM ImmunoTech Announces Closing of its Rights Offering

OCALA, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or…

4 months ago

Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.

March 06, 2026 18:15 ET  | Source: Lisata Therapeutics, Inc. Each Lisata stockholder to receive $5.00 per share in cash…

4 months ago

argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline

Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as the first targeted treatment for patients living with…

4 months ago